Added to YB: 2026-09-03
Pitch date: 2026-08-31
GRFS [bullish]
Grifols, S.A.
+1.16%
current return
Author Info
XIX Value looks for cheap, overlooked, and unpopular stocks, preferably those trading below their Book Value or that are “net-nets”, just as Walter Schloss and the young Warren Buffett did. Sign up for the newsletter.
Company Info
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Market Cap
EUR 5.9B
Pitch Price
EUR 7.74
Price Target
N/A
Dividend
3.05%
EV/EBITDA
9.95
P/E
14.90
EV/Sales
2.31
Sector
Biotechnology
Category
value
Grifols: World-Class Moat, Crisis-Level Price
GRFS: Grifols is a vertically integrated, top-three plasma fractionator whose high-single-digit revenue growth, expanding margins and falling leverage contrast with a crisis valuation of 8.2x adjusted EBITDA. Class B shares offer identical economics to Class A at a 30.5% discount and 11.1x earnings. A US biopharma IPO and higher free cash flow could unlock value, while execution, residual governance concerns and €8.97 billion of net debt remain key risks.
Read full article (8 min)